- Poster presentation
- Open Access
Assessment of cardiovascular magnetic resonance aortic stiffness in patients with increased cardiovascular risk: role of traditional risk factors and lung hyperinflation
© Khanji et al; licensee BioMed Central Ltd. 2015
- Published: 3 February 2015
- Chronic Obstructive Pulmonary Disease
- Cardiovascular Magnetic Resonance
- Chronic Obstructive Pulmonary Disease Patient
- Traditional Risk Factor
- Aortic Stiffness
Cardiovascular disease (CVD) accounts for up to 50% of all deaths in patients with Chronic Obstructive Pulmonary Disease (COPD). Increased arterial stiffness has been shown to predict cardiovascular events beyond the current traditional risk factors.
We sought to assess the relationship of aortic stiffness in patients with elevated global cardiovascular risk against those with COPD and lung hyperinflation.
We assessed 82 patients with elevated cardiovascular risk as estimated by the Qrisk prediction model used in the United Kingdom; 46 were in the HAPPY London study and had normal lung function, 36 had COPD and lung hyperinflation from the DEFLATA study. CMR cine SSFP cross-section images were obtained perpendicular to the ascending thoracic (TAA), descending thoracic (TDA) and abdominal aorta (AbA). Central aortic pulse pressure was measured at the time of the scan (Vicorder device). Strain was derived as relative aortic area change. Distensibility was derived by normalizing strain to central pulse pressure.
Aortic distensibility and strain did not differ between high-risk CVD patients with normal lung function and COPD patients with hyperinflation despite significantly lower CVD risk factors in the COPD group, suggesting that COPD may contribute to stiffness over and above traditional risk factors. Age appears to be the strongest predictor of aortic strain and distensibility. Further studies on the physiological impact of lung hyperinflation on aortic function and the relative contribution of risk factors is warranted to best guide CVD prevention in these high-risk groups.
MYK has received funding from Barts Charity and ISS has received fundings from GSK.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.